{
    "name": "zanamivir",
    "comment": "Rx",
    "other_names": [
        "Relenza"
    ],
    "classes": [
        "Antivirals",
        "Influenza",
        "Neuraminidase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/relenza-zanamivir-342636",
    "pregnancy": {
        "common": [
            "Available data from published studies suggest that use during pregnancy is not associated with an increased risk of birth defects or adverse maternal or fetal outcomes; however, these studies are limited by their small sample sizes, which preclude a definitive assessment of the risk; there are risks to mother and fetus associated with influenza infection in pregnancy; in animal reproduction studies, no adverse developmental effects were observed with intravenous or subcutaneous administration of zanamivir at exposures 300 and 150 times, respectively, the systemic exposure at the maximum recommended human inhalation dose (MRHID) of 10 mg twice daily",
            "Pregnant women are at higher risk of severe complications from influenza, which may lead to adverse pregnancy and/or fetal outcomes, including maternal death, stillbirths, birth defects, preterm delivery, low birth weight,and small for gestational age"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no data on presence of zanamivir in human milk or effects on milk production; there are data from adults that have shown low oral bioavailability of zanamivir; limited data from postmarketing case reports have not suggested a safety concern in infants exposed to breast milk of mothers receiving therapy; drug was present in milk of lactating rats without effect on nursing pups; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed child from drug or underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to zanamivir or formulation, including milk proteins"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Administer only via the Diskhaler inhaler",
                "Allergic-like reactions, including oropharyngeal edema, serious skin rashes, and anaphylaxis reported in postmarketing experience; stop therapy and institute appropriate treatment if an allergic reaction occurs or is suspected",
                "Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions; no information is available regarding treatment of influenza in patients with any medical condition sufficiently severe or unstable to be considered at imminent risk of requiring inpatient management",
                "Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza; this drug has not been shown to prevent such complications",
                "Effective and safe use of the Diskhaler requires proper use to inhale the drug; prescribers should carefully evaluate ability of young children to use delivery system if use is considered",
                "Do not make into an extemporaneous solution for administration by nebulization or mechanical ventilation; fatality reports of hospitalized patients with influenza who received a solution made with Relenza Inhalation Powder administered by nebulization or mechanical ventilation; lactose in this formulation obstructs proper functioning of the equipment",
                "Most effective when used within 24-48 hr of onset of symptoms"
            ],
            "specific": [
                {
                    "type": "Bronchospasm",
                    "description": [
                        "Not recommended for treatment or prophylaxis of influenza in individuals with underlying airway diseases (eg, asthma, COPD); serious cases of bronchospasm, including fatalities, in patients with or without underlying airways disease reported during treatment",
                        "Discontinue therapy in any patient who develops bronchospasm or experience decline in respiratory function; immediate treatment and hospitalization may be required",
                        "Some patients without prior pulmonary disease may have respiratory abnormalities from acute respiratory infection that could resemble adverse drug reactions or increase patient vulnerability to adverse drug reactions",
                        "If use is considered for patient with underlying airway disease, carefully monitor respiratory function, closely observe patient, and have supportive therapy (ie, fast-acting bronchodilators) immediately available"
                    ]
                },
                {
                    "type": "Neuropsychiatric events",
                    "description": [
                        "Influenza can be associated with a variety of neurologic and behavioral symptoms which can include events such as seizures, hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes; these events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease",
                        "There have been postmarketing reports of delirium and abnormal behavior leading to injury in patients with influenza who were receiving therapy; because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made, but they appear to be uncommon",
                        "These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution; the contribution to these events has not been established; patients with influenza should be closely monitored for signs of abnormal behavior",
                        "If neuropsychiatric symptoms occur, the risks and benefits of continuing treatment should be evaluated for each patient"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Live attenuated influenza vaccine (LAIV) intranasal has not been evaluated; however, because of potential interference between these products, LAIV should not be administered within 2 weeks before or 48 hours after administration of this drug, unless medically indicated; the concern about possible interference arises from the potential for antiviral drugs to inhibit replication of live vaccine virus",
                        "Trivalent inactivated influenza vaccine can be administered at any time relative to use of this drug"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "13-24"
        },
        {
            "name": "Throat",
            "percent": "8-19"
        },
        {
            "name": "tonsil pain",
            "percent": "7-17"
        },
        {
            "name": "Cough",
            "percent": "3-13"
        },
        {
            "name": "Viral infection",
            "percent": "2"
        },
        {
            "name": "Dizziness",
            "percent": "3"
        },
        {
            "name": "Nausea",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "adults",
            "percent": "1"
        },
        {
            "name": "children",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "3"
        },
        {
            "name": "adults",
            "percent": "2"
        },
        {
            "name": "children",
            "percent": "2"
        },
        {
            "name": "Sinusitis",
            "percent": "5"
        },
        {
            "name": "Bronchitis",
            "percent": null
        },
        {
            "name": "Infection",
            "percent": null
        },
        {
            "name": "ear",
            "percent": null
        },
        {
            "name": "nose",
            "percent": null
        },
        {
            "name": "throat",
            "percent": null
        },
        {
            "name": "adults",
            "percent": null
        },
        {
            "name": "children",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Allergic Reactions",
            "percent": null
        },
        {
            "name": "Allergic or allergic",
            "percent": null
        },
        {
            "name": "like reaction",
            "percent": null
        },
        {
            "name": "including oropharyngeal edema",
            "percent": null
        },
        {
            "name": "Psychiatric",
            "percent": null
        },
        {
            "name": "Delirium",
            "percent": null
        },
        {
            "name": "including symptoms such as altered level of consciousness",
            "percent": null
        },
        {
            "name": "confusion",
            "percent": null
        },
        {
            "name": "abnormal behavior",
            "percent": null
        },
        {
            "name": "delusions",
            "percent": null
        },
        {
            "name": "hallucinations",
            "percent": null
        },
        {
            "name": "agitation",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "nightmares",
            "percent": null
        },
        {
            "name": "Cardiac",
            "percent": null
        },
        {
            "name": "Arrhythmias",
            "percent": null
        },
        {
            "name": "syncope",
            "percent": null
        },
        {
            "name": "Neurologic",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "vasovagal",
            "percent": null
        },
        {
            "name": "like episodes shortly after administration",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "Bronchospasm",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "Skin",
            "percent": null
        },
        {
            "name": "Facial edema",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "including serious cutaneous reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "erythema multiforme",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        }
    ]
}